The immunoproteasome β5i subunit is a key contributor to ictogenesis in a rat model of chronic epilepsy

Brain, Behavior, and Immunity

Volumn 49, Issue , 2015, Pages 188-196

  Mishto, Michele ^a,b   Raza, Muhammad L ^a   de Biase, Dario ^b   Ravizza, Teresa ^c   Vasuri, Francesco ^d   Martucci, Morena ^b   Keller, Christin ^a   Bellavista, Elena ^b   Buchholz, Tonia J ^e   Kloetzel, Peter M ^a   Pession, Annalisa ^b   Vezzani, Annamaria ^c   Heinemann, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e ONYX PHARMACEUTICALS   (United States)

Author keywords

Neuroinflammation; Pharmaco resistant seizures; Pilocarpine; Proteasome inhibitors

Indexed keywords

DNA; FAMPRIDINE; IMMUNOPROTEASOME BETA5I; MESSENGER RNA; ONX 0914; PROTEASOME; PROTEASOME INHIBITOR; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; OLIGOPEPTIDE; PR-957; PROTEIN SUBUNIT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA5I GENE; BRAIN SLICE; CONTROLLED STUDY; DNA METHYLATION; ENTORHINAL CORTEX; EPILEPTIC FOCUS; EPILEPTIC STATE; EPILEPTOGENESIS; GENE EXPRESSION REGULATION; GLIA CELL; HIPPOCAMPUS; ICTOGENESIS; INTRACELLULAR SIGNALING; MALE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; TEMPORAL LOBE EPILEPSY; TRANSCRIPTION INITIATION; ANIMAL; DISEASE MODEL; ENZYMOLOGY; EPILEPSY; METABOLISM; PATHOPHYSIOLOGY; PROTEIN SUBUNIT; WISTAR RAT;

ANIMALS; DISEASE MODELS, ANIMAL; ENTORHINAL CORTEX; EPILEPSY; HIPPOCAMPUS; MALE; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN SUBUNITS; RATS; RATS, WISTAR; RNA, MESSENGER;

EID: 84940606835     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.05.007     Document Type: Article

References (55)

1. Arciniega M., Beck P., Lange O.F., Groll M., Huber R. Differential global structural changes in the core particle of yeast and mouse proteasome induced by ligand binding. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:9479-9484.
2. Aronica E., Ravizza T., Zurolo E., Vezzani A. Astrocyte immune responses in epilepsy. Glia 2012, 60:1258-1268.
3. Avoli M., Louvel J., Kurcewicz I., Pumain R., Barbarosie M. Extracellular free potassium and calcium during synchronous activity induced by 4-aminopyridine in the juvenile rat hippocampus. J. Physiol. 1996, 493(Pt 3):707-717.
4. Barbarosie M.T., Nagao T., Avoli M. Control of 4-aminopyridine-induced synchronous activity by adenosine A1 and mu-opioid receptor agonists in adult rat hippocampus. Neurosci. Lett. 1994, 182:208-212.
5. Barna B., Szasz A., Vilagi I., Szente M. Anticonvulsive effect of AMPA receptor antagonist GYKI 52466 on 4-aminopyridine-induced cortical ictal activity in rat. Brain Res. Bull. 2000, 51:241-248.
6. Basler M., Mundt S., Muchamuel T., Moll C., Jiang J., Groettrup M., Kirk C.J. Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol. Med. 2014, 6:226-238.
7. Bellavista E., Andreoli F., Parenti M.D., Martucci M., Santoro A., Salvioli S., Capri M., Baruzzi A., Del Rio A., Franceschi C., Mishto M. Immunoproteasome in cancer and neuropathologies: a new therapeutic target?. Curr. Pharm. Des. 2013, 19:702-718.
8. Bellavista E., Santoro A., Galimberti D., Comi C., Luciani F., Mishto M. Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis. Autoimmune Dis. 2014, 2014:739705.
9. Bruckner C., Heinemann U. Effects of standard anticonvulsant drugs on different patterns of epileptiform discharges induced by 4-aminopyridine in combined entorhinal cortex-hippocampal slices. Brain Res. 2000, 859:15-20.
10. 2+-and 4-aminopyridine-induced seizure-like events reveals characteristic features in adult rat limbic system. Epilepsia 2000, 41:635-641.
11. Cai F., Frey J.U., Sanna P.P., Behnisch T. Protein degradation by the proteasome is required for synaptic tagging and the heterosynaptic stabilization of hippocampal late-phase long-term potentiation. Neuroscience 2010, 169:1520-1526.
12. Chiavegato A., Zurolo E., Losi G., Aronica E., Carmignoto G. The inflammatory molecules IL-1beta and HMGB1 can rapidly enhance focal seizure generation in a brain slice model of temporal lobe epilepsy. Front. Cell. Neurosci. 2014, 8:155.
13. Dong C., Bach S.V., Haynes K.A., Hegde A.N. Proteasome modulates positive and negative translational regulators in long-term synaptic plasticity. J. Neurosci. 2014, 34:3171-3182.
14. Fonseca R., Vabulas R.M., Hartl F.U., Bonhoeffer T., Nagerl U.V. A balance of protein synthesis and proteasome-dependent degradation determines the maintenance of LTP. Neuron 2006, 52:239-245.
15. Fueta Y., Avoli M. Effects of antiepileptic drugs on 4-aminopyridine-induced epileptiform activity in young and adult rat hippocampus. Epilepsy Res. 1992, 12:207-215.
16. Gabriel S., Njunting M., Pomper J.K., Merschhemke M., Sanabria E.R., Eilers A., Kivi A., Zeller M., Meencke H.J., Cavalheiro E.A., Heinemann U., Lehmann T.N. Stimulus and potassium-induced epileptiform activity in the human dentate gyrus from patients with and without hippocampal sclerosis. J. Neurosci. 2004, 24:10416-10430.
17. Giannini C., Kloss A., Gohlke S., Mishto M., Nicholson T.P., Sheppard P.W., Kloetzel P.M., Dahlmann B. Poly-Ub-substrate-degradative activity of 26S proteasome is not impaired in the aging rat brain. PLoS One 2013, 8:e64042.
18. Gohlke S., Mishto M., Textoris-Taube K., Keller C., Giannini C., Vasuri F., Capizzi E., D'Errico-Grigioni A., Kloetzel P.M., Dahlmann B. Molecular alterations in proteasomes of rat liver during aging result in altered proteolytic activities. Age (Dordr.) 2014, 36:57-72.
19. Groettrup M., Kirk C.J., Basler M. Proteasomes in immune cells: more than peptide producers?. Nat. Rev. Immunol. 2010, 10:73-78.
20. Hamilton A.M., Oh W.C., Vega-Ramirez H., Stein I.S., Hell J.W., Patrick G.N., Zito K. Activity-dependent growth of new dendritic spines is regulated by the proteasome. Neuron 2012, 74:1023-1030.
21. Heinemann U., Lux H.D. Ceiling of stimulus induced rises in extracellular potassium concentration in the cerebral cortex of cat. Brain Res. 1977, 120:231-249.
22. Huber E.M., Basler M., Schwab R., Heinemeyer W., Kirk C.J., Groettrup M., Groll M. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 2012, 148:727-738.
23. Iori V., Maroso M., Rizzi M., Iyer A.M., Vertemara R., Carli M., Agresti A., Antonelli A., Bianchi M.E., Aronica E., Ravizza T., Vezzani A. Receptor for advanced glycation end products is upregulated in temporal lobe epilepsy and contributes to experimental seizures. Neurobiol. Dis. 2013, 58:102-114.
24. Jandova K., Pasler D., Antonio L.L., Raue C., Ji S., Njunting M., Kann O., Kovacs R., Meencke H.J., Cavalheiro E.A., Heinemann U., Gabriel S., Lehmann T.N. Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices. Brain 2006, 129:3290-3306.
25. Kobow K., El-Osta A., Blumcke I. The methylation hypothesis of pharmacoresistance in epilepsy. Epilepsia 2013, 54(Suppl. 2):41-47.
26. Kwon Y.S., Pineda E., Auvin S., Shin D., Mazarati A., Sankar R. Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain. J. Neuroinflam. 2013, 10:30.
27. Louvel J., Papatheodoropoulos C., Siniscalchi A., Kurcewicz I., Pumain R., Devaux B., Turak B., Esposito V., Villemeure J.G., Avoli M. GABA-mediated synchronization in the human neocortex: elevations in extracellular potassium and presynaptic mechanisms. Neuroscience 2001, 105:803-813.
28. Maroso M., Balosso S., Ravizza T., Liu J., Aronica E., Iyer A.M., Rossetti C., Molteni M., Casalgrandi M., Manfredi A.A., Bianchi M.E., Vezzani A. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat. Med. 2010, 16:413-419.
29. Maroso M., et al. Interleukin-1beta biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics 2011, 8:304.
30. Mishto M., Bellavista E., Santoro A., Stolzing A., Ligorio C., Nacmias B., Spazzafumo L., Chiappelli M., Licastro F., Sorbi S., Pession A., Ohm T., Grune T., Franceschi C. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol. Aging 2006, 27:54-66.
31. Mishto M., Santoro A., Bellavista E., Sessions R., Textoris-Taube K., Dal Piaz F., Carrard G., Forti K., Salvioli S., Friguet B., Kloetzel P.M., Rivett A.J., Franceschi C. A structural model of 20S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms. Biol. Chem. 2006, 387:417-429.
32. Mishto M., Bellavista E., Ligorio C., Textoris-Taube K., Santoro A., Giordano M., D'Alfonso S., Listi F., Nacmias B., Cellini E., Leone M., Grimaldi L.M., Fenoglio C., Esposito F., Martinelli-Boneschi F., Galimberti D., Scarpini E., Seifert U., Amato M.P., Caruso C., Foschini M.P., Kloetzel P.M., Franceschi C. Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. PLoS One 2010, 5:e9287.
33. Mishto M., Ligorio C., Bellavista E., Martucci M., Santoro A., Giulioni M., Marucci G., Franceschi C. Immunoproteasome expression is induced in mesial temporal lobe epilepsy. Biochem. Biophys. Res. Commun. 2011, 408:65-70.
34. Mishto M., Liepe J., Textoris-Taube K., Keller C., Henklein P., Weberruss M., Dahlmann B., Enenkel C., Voigt A., Kuckelkorn U., Stumpf M.P., Kloetzel P.M. Proteasome isoforms exhibit only quantitative differences in cleavage and epitope generation. Eur. J. Immunol. 2014.
35. Muchamuel T., Basler M., Aujay M.A., Suzuki E., Kalim K.W., Lauer C., Sylvain C., Ring E.R., Shields J., Jiang J., Shwonek P., Parlati F., Demo S.D., Bennett M.K., Kirk C.J., Groettrup M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med. 2009, 15:781-787.
36. Neher E., Lux H.D. Rapid changes of potassium concentration at the outer surface of exposed single neurons during membrane current flow. J. Gen. Physiol. 1973, 61:385-399.
37. Parlati F., Lee S.J., Aujay M., Suzuki E., Levitsky K., Lorens J.B., Micklem D.R., Ruurs P., Sylvain C., Lu Y., Shenk K.D., Bennett M.K. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009, 114:3439-3447.
38. Paxinos G., Watson C., Pennisi M., Topple A. Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight. J. Neurosci. Methods 1985, 13:139-143.
39. Pintado C., Gavilan M.P., Gavilan E., Garcia-Cuervo L., Gutierrez A., Vitorica J., Castano A., Rios R.M., Ruano D. Lipopolysaccharide-induced neuroinflammation leads to the accumulation of ubiquitinated proteins and increases susceptibility to neurodegeneration induced by proteasome inhibition in rat hippocampus. J. Neuroinflam. 2012, 9:87.
40. Pitkanen A., Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol. 2011, 10:173-186.
41. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32:281-294.
42. Ravizza T., Balosso S., Vezzani A. Inflammation and prevention of epileptogenesis. Neurosci. Lett. 2011, 497:223-230.
43. Rojas A., Jiang J., Ganesh T., Yang M.S., Lelutiu N., Gueorguieva P., Dingledine R. Cyclooxygenase-2 in epilepsy. Epilepsia 2014, 55:17-25.
44. Sandow N., Zahn R.K., Gabriel S., Heinemann U., Lehmann T.N. Glutamine induces epileptiform discharges in superficial layers of the medial entorhinal cortex from pilocarpine-treated chronic epileptic rats in vitro. Epilepsia 2009, 50:849-858.
45. Schubert P., Heinemann U. Adenosine antagonists combined with 4-aminopyridine cause partial recovery of synaptic transmission in low Ca media. Exp. Brain Res. 1988, 70:539-549.
46. Tai H.C., Schuman E.M. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat. Rev. Neurosci. 2008, 9:826-838.
47. Uva L., Trombin F., Carriero G., Avoli M., de Curtis M. Seizure-like discharges induced by 4-aminopyridine in the olfactory system of the in vitro isolated guinea pig brain. Epilepsia 2013, 54:605-615.
48. Vezzani A., Viviani B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology 2014.
49. Vezzani A., French J., Bartfai T., Baram T.Z. The role of inflammation in epilepsy. Nat. Rev. Neurol. 2011, 7:31-40.
50. Vezzani A., Maroso M., Balosso S., Sanchez M.A., Bartfai T. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav. Immun. 2011, 25:1281-1289.
51. Vezzani A., Friedman A., Dingledine R.J. The role of inflammation in epileptogenesis. Neuropharmacology 2013, 69:16-24.
52. Weaver D.F., Pohlmann-Eden B. Pharmacoresistant epilepsy: unmet needs in solving the puzzle(s). Epilepsia 2013, 54(Suppl. 2):80-85.
53. Zahn R.K., Tolner E.A., Derst C., Gruber C., Veh R.W., Heinemann U. Reduced ictogenic potential of 4-aminopyridine in the perirhinal and entorhinal cortex of kainate-treated chronic epileptic rats. Neurobiol. Dis. 2008, 29:186-200.
54. Zahn R.K., Liotta A., Kim S., Sandow N., Heinemann U. Reduced ictogenic potential of 4-aminopyridine in the hippocampal region in the pilocarpine model of epilepsy. Neurosci. Lett. 2012, 513:124-128.
55. Zurolo E., Iyer A., Maroso M., Carbonell C., Anink J.J., Ravizza T., Fluiter K., Spliet W.G., van Rijen P.C., Vezzani A., Aronica E. Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. Brain 2011, 134:1015-1032.